Ozempic maker Novo Nordisk and Weight Watchers have entered a deal to increase the accessibility of weight loss drug Wegovy. Beginning July 1, Weight Watchers Clinic members can avail of Wegovy via CenterWell Pharmacy at an introductory price of $299.
Hims & Hers Fallout
This expansion follows Novo Nordisk’s termination of its deal with Hims & Hers, citing concerns over compounded semaglutide. As a result, Novo is redirecting its focus toward trusted partnerships that prioritize patient safety.
Currently, Wegovy remains the only FDA-approved semaglutide medication for chronic weight management. Today, nearly 1.5 million people in the U.S. use it.
Importantly, this partnership gives users access to the branded drug through CenterWell, Humana’s specialty pharmacy, via the WW Clinic platform.
Novo Nordisk’s $299 Wegovy Offer
Through July 31, eligible new patients can receive Wegovy for $299. Last month, WW Clinic offered the medication for $199, helping patients access treatment more affordably. Meanwhile, for subsequent months, self-paying patients need to pay $499 per month.
Moreover, members will receive home delivery, shipment tracking, and prescription management via an integrated online dashboard.
Novo Nordisk & Weight Watchers
Scott Honken, Chief Commercial Officer at Weight Watchers, praised the expanded partnership.
“In a market increasingly cluttered with hype and shortcuts, WeightWatchers remains the trusted leader, bringing together access to safe, FDA-approved medication and best-in-class lifestyle support, setting the bar for the gold standard of responsible weight management,” said Weight Watchers Chief Commercial Officer Scott Honken.
Similarly, Novo Nordisk echoed enthusiasm. Dave Moore, Executive Vice President of Commercial Strategy, emphasized the importance of aligned health goals.
“As we work to expand access to life-changing, FDA-approved treatments like Wegovy®, it is essential that we partner with organizations that share our values and focus on improving long-term outcomes,” said Novo Nordisk Executive Vice President for U.S. Operations.
Strategic Timing of Novo Nordisk
Notably, this collaboration comes at a critical time for both companies. Earlier in May, Weight Watchers filed for bankruptcy to shed over $1 billion in debt. Overall, this move is part of its broader pivot toward clinically guided weight loss.
Meanwhile, Novo Nordisk is defending its blockbuster drug from unauthorized compounded versions by strengthening official distribution channels. Additionally, the company has existing partnerships with Ro and LifeMD.
Impact and Future Research
Wegovy’s integration with WW Clinic has already shown promising outcomes. According to internal data, members using GLP-1 medications like Wegovy lost an average of 21% of their body weight within 12 months.
Consequently, both companies plan to conduct real-world studies to evaluate long-term effectiveness and healthcare savings. In time, these studies will help establish Wegovy’s role within a comprehensive care model.
New Weight Management Model
This Novo Nordisk-Weight Watchers partnership blends pharmaceutical and behavioral support in a way that prioritizes clinical integrity and consumer convenience. The $299 Wegovy offer runs through July 31, encouraging interested members to act quickly.
Looking ahead, this could become a blueprint for future collaborations between wellness platforms and drug manufacturers.
By integrating treatment with lifestyle coaching and pharmacy delivery, Novo Nordisk and Weight Watchers are helping redefine obesity care in America.
Photo: Mike Mozart from Funny YouTube, USA, CC BY 2.0, via Wikimedia Commons
